The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tmoyan N.A.

Chazov National Medical Research Centre of Cardiology

Ezhov M.V.

Chazov National Medical Research Center of Cardiology

Afanasieva O.I.

Chazov National Medical Research Centre of Cardiology

Tyurina A.V.

Chazov National Medical Research Centre of Cardiology

Alekseeva I.A.

Chazov National Medical Research Centre of Cardiology

Kolmakova T.E.

Chazov National Medical Research Centre of Cardiology

Klesareva E.A.

Chazov National Medical Research Centre of Cardiology

Afanasieva M.I.

Chazov National Medical Research Centre of Cardiology

Razova O.A.

Chazov National Medical Research Centre of Cardiology

Pokrovsky S.N.

Chazov National Medical Research Centre of Cardiology

Lipoprotein(a) as an independent factor associated with intermittent claudication

Authors:

Tmoyan N.A., Ezhov M.V., Afanasieva O.I., Tyurina A.V., Alekseeva I.A., Kolmakova T.E., Klesareva E.A., Afanasieva M.I., Razova O.A., Pokrovsky S.N.

More about the authors

Journal: Russian Cardiology Bulletin. 2025;20(3): 42‑47

DOI: 10.17116/Cardiobulletin20252003142

Read: 272 times

Download PDF (RU)
Contact the author
Table of contents

LIPOPROTEIN(A) AS AN INDEPENDENT FACTOR ASSOCIATED WITH INTERMITTENT CLAUDICATION
LIPOPROTEIN(A) AS AN INDEPENDENT FACTOR ASSOCIATED WITH INTERMITTENT CLAUDICATION

To cite this article:

Tmoyan NA, Ezhov MV, Afanasieva OI, et al. . Lipoprotein(a) as an independent factor associated with intermittent claudication. Russian Cardiology Bulletin. 2025;20(3):42‑47. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20252003142

 
ЭндоКард
Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Prevalence and role of elevated serum lipo­protein(a) in patients with myocardial infa­rction acco­rding to the Russian regi­ster of acute myocardial infa­rction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48
Asso­ciations of aortic valve area and calcification with diastolic heart function and high lipo­protein(a) levels in a popu­lation study. Russian Cardiology Bulletin. 2025;(2):27-36
The improvement of the specialized medi­cal care for patients with peri­pheral arte­rial athe­rosclerosis in the Yaro­slavl region. Russian Journal of Preventive Medi­cine. 2024;(12):16-23
Predictors of myocardial infa­rction in patients with stable peri­pheral artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):61-65
Giant popliteal artery aneurysm. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):115-119
Pote­ntial for the use of nutraceuticals for hype­rlipidemia correction. Russian Journal of Preventive Medi­cine. 2025;(3):40-45
Increased expression of circular RNA circSPARC and circTMEM181 in coro­nary athe­rosclerosis. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):24-29
The influence of demo­graphic factors and major como­rbidities on serum circulating regu­latory microRNAs in patients with coro­nary artery athe­rosclerosis and thoracic aortic aneurysm: a single-center cohort study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):174-182
The place of non-high-density lipo­protein cholesterol and triglycerides in the asse­ssment of cardiovascular risk: Reso­lution of the Panel of Expe­rts. Russian Journal of Preventive Medi­cine. 2025;(4):7-15
Neutrophil elastase as a promising biomarker of low-grade inflammation in chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(4):142-148
Abstract:

OBJECTIVE

To evaluate the relationship between lipoprotein(a) [Lp(a)], apoprotein(a) phenotypes, and inflammatory markers depending on symptoms of lower extremity artery atherosclerosis.

MATERIAL AND METHODS

The study included 710 patients with lower extremity artery atherosclerosis (median age 66 years, 71% men). Intermittent claudication was diagnosed in 214 patients, 496 patients had asymptomatic lower extremity artery atherosclerosis. Classic risk factors were assessed in all patients. Serum lipid levels, Lp(a), and C-reactive protein were measured.

RESULTS

Patients with asymptomatic lower extremity artery atherosclerosis and intermittent claudication were comparable in age, incidence of arterial hypertension, type 2 diabetes mellitus and lipid spectrum. Men, smoking and elevated Lp(a) levels were more common among patients with intermittent claudication compared to those with asymptomatic lower limb artery disease. The odds ratio of intermittent claudication in Lp(a) ≥30 mg/dL was 2.3 (95% CI 1.6—3.2; p<0.01) compared to patients with Lp(a) levels <30 mg/dL. According to logistic regression analysis, elevated Lp(a) was associated with intermittent claudication after accounting for other risk factors.

CONCLUSION

Elevated lipoprotein(a), as well as smoking and male gender, are associated with intermittent claudication.

Keywords:

lipoprotein(a)
atherosclerosis
lower limb artery atherosclerosis
peripheral artery disease
intermittent claudication

Authors:

Tmoyan N.A.

Chazov National Medical Research Centre of Cardiology

Ezhov M.V.

Chazov National Medical Research Center of Cardiology

Afanasieva O.I.

Chazov National Medical Research Centre of Cardiology

Tyurina A.V.

Chazov National Medical Research Centre of Cardiology

Alekseeva I.A.

Chazov National Medical Research Centre of Cardiology

Kolmakova T.E.

Chazov National Medical Research Centre of Cardiology

Klesareva E.A.

Chazov National Medical Research Centre of Cardiology

Afanasieva M.I.

Chazov National Medical Research Centre of Cardiology

Razova O.A.

Chazov National Medical Research Centre of Cardiology

Pokrovsky S.N.

Chazov National Medical Research Centre of Cardiology

Received:

30.01.2025

Accepted:

27.03.2025

Close metadata

References:

  1. Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379-381.  https://doi.org/10.1016/j.atherosclerosis.2018.05.033
  2. Dua A, Lee CJ. Epidemiology of Peripheral Arterial Disease and Critical Limb Ischemia. Tech Vasc Interv Radiol. 2016;19(2):91-95.  https://doi.org/10.1053/j.tvir.2016.04.001
  3. Mazzolai L, Teixido-Tura G, Lanzi S, et al, ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). European Heart Journal. 2024;45(36):3538-3700. https://doi.org/10.1093/eurheartj/ehae179
  4. Bonaca MP, Gutierrez JA, Creager MA, et al. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation. 2016;133(10):997-1005. https://doi.org/10.1161/CIRCULATIONAHA.115.019355
  5. Bhatt DL, Peterson ED, Harrington RA, et al; CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30(10):1195-202.  https://doi.org/10.1093/eurheartj/ehp099
  6. Tmoyan NA, Afanasieva OI, Ezhov MV, et al. Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease. J Cardiovasc Dev Dis. 2021;8(2):11.  https://doi.org/10.3390/jcdd8020011
  7. Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, et al. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. J Cell Physiol. 2018;233(11):8508-8525.
  8. Afanasieva OI, Ezhov MV, Razova OA, et al. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Atherosclerosis. 2018;277:477-482.  https://doi.org/10.1016/j.atherosclerosis.2018.08.011
  9. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509-1526. https://doi.org/10.1161/CIRCRESAHA.116.303849
  10. Tsimikas S. Lipoprotein(a) in the Year 2024: A Look Back and a Look Ahead. Arterioscler Thromb Vasc Biol. 2024;44(7):1485-1490. https://doi.org/10.1161/ATVBAHA.124.319483
  11. Lange KS, Nave AH, Liman TG, et al. Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke. Stroke. 2017;48(1):36-42.  https://doi.org/10.1161/STROKEAHA.116.014436
  12. Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853. https://doi.org/10.1093/eurheartj/ehq386
  13. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45.  https://doi.org/10.1161/01.cir.0000437738.63853.7a
  14. Catapano AL, Reiner Z, De Backer G, et al; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46.  https://doi.org/10.1016/j.atherosclerosis.2011.06.028
  15. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61(11):1146-1156. https://doi.org/10.1016/j.jacc.2012.12.023
  16. Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.  https://doi.org/10.1093/eurheartj/ehz455
  17. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5471
  18. Zafrir B, Aker A, Saliba W. Extreme lipoprotein(a) in clinical practice: A cross sectional study. Int J Cardiol Cardiovasc Risk Prev. 2023;16:200173. https://doi.org/10.1016/j.ijcrp.2023.200173
  19. Sanchez Muñoz-Torrero JF, Rico-Martín S, Álvarez LR, et al; FRENA Investigators. Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis. 2018;276:10-14.  https://doi.org/10.1016/j.atherosclerosis.2018.07.001
  20. Wang H, Wu P, Jiang D, et al. Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a dose-response meta-analysis. Eur J Med Res. 2022;27(1):261.  https://doi.org/10.1186/s40001-022-00870-1
  21. Yanaka K, Akahori H, Imanaka T, et al. Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions. J Atheroscler Thromb. 2021;28(5):555-561.  https://doi.org/10.5551/jat.56457
  22. Dieplinger B, Lingenhel A, Baumgartner N, et al. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem. 2007;53(7):1298-1305. https://doi.org/10.1373/clinchem.2007.088013
  23. Tmoyan NA, Afanasieva OI, Klesareva EA, et al. The Association of Lipoprotein(a), Apolipoprotein(a) Phenotypes and Autoantibodies to Lipoprotein(a) With Lower Extremity Artery Disease. Kardiologiia. 2018;58(12):45-51. (In Russ.). https://doi.org/10.18087/cardio.2018.12.10176
  24. Tmoyan NA, Afanasieva OI, Ezhov MV, et al. Lipoprotein(a) Level, Apolipoprotein(a) Polymorphism and Autoantibodies Against Lipoprotein(a) in Patients with Stenotic Carotid Atherosclerosis. Kardiologiia. 2019; 59(12):20-27. (In Russ.). https://doi.org/10.18087/cardio.2019.12.n727
  25. Laschkolnig A, Kollerits B, Lamina C, et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res. 2014;103(1):28-36.  https://doi.org/10.1093/cvr/cvu107
  26. Burger PM, Pradhan AD, Dorresteijn JAN, et al; Utrecht Cardiovascular Cohort-Second Manifestations of ARTerial disease study group. C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations. Am J Cardiol. 2023;197:13-23.  https://doi.org/10.1016/j.amjcard.2023.03.025
  27. Puri R, Nissen SE, Arsenault BJ, et al. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial. JAMA Cardiol. 2020;5(10):1136-1143. https://doi.org/10.1001/jamacardio.2020.241
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.